Staff Profile

Work in our group is funded by Prostate Cancer UK. We are investigating how glycans influence prostate cancer cell behaviour, testing if they can be targeted by new treatments, and seeing if we can detect them as part of a new non-invasive test to improve diagnosis.

Areas of expertise

• Glycosylation in cancer
• Prostate cancer

Editorial Board: Scientific Reports

Google scholar: Click here

• Articles

  • Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn AC, Hodgson K, Kendall H, Frame FM, Maitland N, Coffey K, Strand DW, Robson CN, Elliott DJ, Heer R, Macauley M, Munkley J, Gaughan L, Leslie J, Scott E. ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Communications Biology 2024, 7(1), 276.
  • Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023, 42, 926–937.
  • Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, Zhou Y, He J, Bermudez A, Garcia Marques FJ, Bastian K, Hysenaj G, Archer Goode E, Heer R, Pitteri S, Wang N, Elliott DJ, Munkley J. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. Scientific Reports 2023, 13(1), 17031.
  • Orozco-Moreno M, Visser EA, Hodgson K, Hipgrave Ederveen AL, Bastian K, Archer Goode E, Öztürk O, Pijnenborg JFA, Eerden N, Moons SJ, Rossing E, Wang N, de Haan N, Büll C, Boltje TJ, Munkley J. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Glycobiology 2023, 33(12), 1155-1171.
  • Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Garcia Marques FJ, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. Journal of Pathology 2023, 261(1), 71-84.
  • Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn A, Hodgson K, Kendall H, Frame FM, Maitland NM, Coffey K, Robson CN, Elliott DJ, Heer R, Macauley MS, Munkley J, Gaughan L, Leslie J, Scott E. ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. bioRxiv 2023.
  • Siachisumo C*, Luzzi S*, Aldalaqan S*, Hysenaj G, Dalgliesh C, Cheung K, Gazzara M, Yonchev ID, James K, Kheirollahi Chadegani M, Ehrmann I, Smith GR, Cockell SJ, Munkley J, Barash Y, Wilson SA, Elliott DJ. An anciently diverged family of RNA binding proteins maintain correct splicing of ultra-long exons through cryptic splice site repression. Chromosomes and Gene Expression 2023, 38(12), 2163-2172.
  • Scott E, Garnham R, Cheung K, Duxfield A, Elliott DJ, Munkley J. Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer. International Journal of Molecular Sciences 2022, 23(15), 8184.
  • Duxfield A, Munkley J, Briggs MD, Dennis EP. CRELD2 is a novel modulator of calcium release and calcineurin-NFAT signalling during osteoclast differentiation. Scientific Reports 2022, 12(1), 13884.
  • Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 2019, 8, e47678.
  • Coomer AO, Black F, Greystoke A, Munkley J, Elliott DJ. Alternative splicing in lung cancer. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms 2019, 1862(11-12), 194388.
  • Munkley J, Maia TM, Ibarluzea N, Livermore KE, Vodak D, Ehrmann I, James K, Rajan P, Barbosa-Morais NL, Elliott DJ. Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. F1000 Research 2018, 7(7), 1189.
  • Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Leung HY, Mills IG, Robson CN, Rajan P, Elliott DJ. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports 2017, 7(1), 5249.
  • Munkley J, Livermore K, Rajan P, Elliott DJ. RNA splicing and splicing regulator changes in prostate cancer pathology. Human Genetics 2017, 136(9), 1143-1154.
  • Munkley J. Glycosylation is a global target for androgen control in prostate cancer cells. Endocrine Related Cancer 2017, 24, R49-R64.
  • Munkley J. The Role of Sialyl-Tn in Cancer. International Journal of Molecular Sciences 2016, 17(3), 275.
  • Munkley J, Mills IG, Elliott DJ. The role of glycans in the development and progression of prostate cancer. Nature Reviews Urology 2016, 13(6), 324-333.
  • Munkley J, Elliott DJ. Sugars and cell adhesion: the role of ST6GalNAc1 in prostate cancer progression. Cancer Cell & Microenvironment 2016, 3(1), e1174.
  • Neganova A, Shmeleva E, Munkley J, Chichagova V, Anyfantis G, Anderson R, Passos AJ, Elliott DJ, Armstrong L, Lako M. JNK/SAPK signalling is essential for efficient reprogramming of human fibroblasts to induced pluripotent stem cells. Stem Cells 2016, 34(5), 1198-1212.
  • Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget 2016, 7, 35478-35489.
  • Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. eBioMedicine 2016, 8, 103-116.
  • Livermore KE, Munkley J, Elliott DJ. Androgen receptor in prostate cancer. AIMS Molecular Science 2016, 3(2), 280-299.
  • Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M, Leung HY, Robson CN, Harries LW, Rajan P, Elliott DJ. The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience 2015, 2(9).
  • Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG, Elliott DJ. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget 2015, 6(33), 34358-34374.
  • Wilson B, Strong A, O'Kelly S, Munkley J, Stark Z. Metronidazole Toxicity in Cockayne Syndrome: A Case Series. Pediatrics 2015, 136(3), e706-e708.
  • Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P, Elliott DJ. Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer. BMC Cancer 2015, 15, 9.
  • Munkley J, Rajan P, Lafferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY, Elliott DJ. A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. OncoTarget 2014, 5(1), 131-139.
  • Boczonadi V, Muller JS, Pyle A, Munkley J, Dor T, Quartararo J, Ferrero I, Karcagi V, Giunta M, Polvikoski T, Birchall D, Princzinger A, Cinnamon Y, Lutzkendorf S, Piko H, Reza M, Florez L, Santibanez-Koref M, Griffin H, Schuelke M, Elpeleg O, Kalaydjieva L, Lochmuller H, Elliott DJ, Chinnery PF, Edvardson S, Horvath R. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nature Communications 2014, 5, 4287.
  • Munkley J, Copeland NA, Moignard V, Knight JR, Greaves E, Ramsbottom SA, Pownall ME, Southgate J, Ainscough JF, Coverley D. Cyclin E is recruited to the nuclear matrix during differentiation, but is not recruited in cancer cells. Nucleic Acids Research 2011, 39(7), 2671-7.

• Reviews

  • Advani R, Luzzi S, Scott E, Dalgliesh C, Weischenfeldt J, Munkley J, Elliott DJ. Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer. Oncogene 2023, 42, 3161–3168.
  • Munkley J. Aberrant Sialylation in Cancer: Therapeutic Opportunities. Cancers 2022, 14(17), 4248.
  • Bastian K, Scott E, Elliott DJ, Munkley J. Fut8 alpha-(1,6)-fucosyltransferase in cancer. International Journal of Molecular Sciences 2021, 22(1), 1-22.
  • Scott E, Elliott DJ, Munkley J. Tumour associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta 2020, 502, 167-173.
  • Munkley J. The glycosylation landscape of pancreatic cancer. Oncology Letters 2019, 17(3), 2569-2575.
  • Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines 2019, 6(4), 102.
  • Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: A key player in cancer (Review). Oncology Letters 2019, 18(2), 983-989.
  • Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. International Journal of Molecular Sciences 2019, 20(6), 1389.